Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.40+0.40 (+2.22%)
Close on Nov 18, 2026Market cap $2.94BP/E –Yield –
Denali Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Denali Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$437.46M. For fiscal 2025 it was -$422.10M. The highest annual figure on record is $413.06M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$422.10M | – |
| FY2024 | Dec 31, 2024 | -$363.61M | – |
| FY2023 | Dec 31, 2023 | -$370.93M | – |
| FY2022 | Dec 31, 2022 | -$262.55M | – |
| FY2021 | Dec 31, 2021 | -$219.89M | -153.2% |
| FY2020 | Dec 31, 2020 | $413.06M | – |
| FY2019 | Dec 31, 2019 | -$169.50M | -462.8% |
| FY2018 | Dec 31, 2018 | $46.72M | – |
| FY2017 | Dec 31, 2017 | -$79.51M | – |
| FY2016 | Dec 31, 2016 | -$78.04M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$97.81M | – |
| Q1 FY2026 | Mar 31, 2026 | -$133.67M | – |
| Q4 FY2025 | Dec 31, 2025 | -$100.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$105.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$79.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$136.55M | – |
| Q4 FY2024 | Dec 31, 2024 | -$88.81M | – |
| Q3 FY2024 | Sep 30, 2024 | -$63.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$96.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$115.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$100.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$89.43M | – |
| Q2 FY2023 | Jun 30, 2023 | -$119.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$61.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$77.51M | – |
| Q3 FY2022 | Sep 30, 2022 | -$63.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$45.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$76.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$68.55M | -113.4% |
| Q3 FY2021 | Sep 30, 2021 | -$43.31M | – |
| Q2 FY2021 | Jun 30, 2021 | -$54.99M | – |
| Q1 FY2021 | Mar 31, 2021 | -$53.04M | – |
| Q4 FY2020 | Dec 31, 2020 | $512.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$620.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$43.67M | – |
| Q1 FY2020 | Mar 31, 2020 | -$55.37M | – |
| Q4 FY2019 | Dec 31, 2019 | -$50.42M | -155.0% |
| Q3 FY2019 | Sep 30, 2019 | -$33.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$53.45M | – |
| Q1 FY2019 | Mar 31, 2019 | -$32.35M | -197.9% |
| Q4 FY2018 | Dec 31, 2018 | $91.75M | – |
| Q3 FY2018 | Sep 30, 2018 | -$35.67M | – |
| Q2 FY2018 | Jun 30, 2018 | -$42.40M | – |
| Q1 FY2018 | Mar 31, 2018 | $33.04M | – |
| Q4 FY2017 | Dec 31, 2017 | -$19.41M | – |
| Q3 FY2017 | Sep 30, 2017 | -$22.29M | – |
| Q2 FY2017 | Jun 30, 2017 | -$18.14M | – |
| Q1 FY2017 | Mar 31, 2017 | -$19.68M | – |
See a number that looks wrong?